Business Wire

“Look for the WELL Health-Safety Seal” Public Awareness Campaign Launches, Featuring Lady Gaga, Jennifer Lopez, Michael B. Jordan, Robert DeNiro, Venus Williams, Wolfgang Puck, Deepak Chopra and 17th U.S. Surgeon General Richard Carmona

25.1.2021 16:00:00 EET | Business Wire | Press release

Share

As the world continues to battle COVID-19 and communities strive to get back to business, it is more important than ever to raise confidence in the safety of buildings and shared spaces. Today, Lady Gaga, Jennifer Lopez, Michael B. Jordan, Robert DeNiro, Venus Williams, Wolfgang Puck, Deepak Chopra and 17th Surgeon General Richard Carmona came together in a new integrated ad campaign to raise awareness about the importance of the WELL Health-Safety Rating, an evidence-based third-party designation to verify that a building or space has taken the necessary steps to prioritize the health and safety of their staff, visitors and other stakeholders. The ambassadors encourage people to look for buildings and spaces with the WELL Health-Safety seal on their windows or doors to feel more confident in their decision to go inside.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005216/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

WELL Health-Safety Seal (Photo: Business Wire)

This national advertising campaign, a first from the International WELL Building Institute (IWBI), the global authority on how we can use our buildings and communities to advance the health and well-being of the people inside, explains the importance of health and safety through building design and operations as well as organizational policy, and sheds light on what the featured ambassadors have missed most during the pandemic. From Jennifer Lopez’s family movie nights to Robert DeNiro missing a “variety in existence,” each of these cultural influencers are feeling the longing for shared connection as much as the rest of us, even beyond the changes to their respective industries and day-to-day lives.

“This is more than an awareness campaign; it’s meant to ignite a movement. These ambassadors and cultural influencers are partnering with us because they truly believe in the mission – and how critical it is – to make buildings and shared spaces center on health going forward,” said Paul Scialla, Founder of the International WELL Building Institute and CEO of its parent company, Delos. “To succeed at scale means we are improving indoor spaces to help ensure that the people who visit them can be healthier and safer. This is a win for everyone involved.”

The WELL Health-Safety Rating brings together building expertise and nearly a decade of health science to promote indoor safety, creating an efficient and cost-effective opportunity to guide, validate, recognize and scale efforts to manage critical health and safety issues in shared spaces. The WELL Health-Safety Rating examines 22 features across five core areas – Cleaning and Sanitization Procedures, Emergency Preparedness Programs, Health Service Resources, Air and Water Quality Management, and Stakeholder Engagement and Communication – and requires a minimum of 15 criteria be met in order to achieve the rating and be awarded the WELL Health-Safety seal.

As such, the seal is a symbol of trust and confidence that is backed by science, structure and, most importantly, third-party verification. IWBI has seen thousands of buildings enroll in the program since its launch in July 2020, and expects significant global adoption to continue in 2021 and beyond.

“While the WELL Health-Safety Rating was a response to this moment in time, it was developed to address broader health and safety-related issues well into the future,” said Rachel Hodgdon, President and CEO of the International WELL Building Institute. “We collaborated with our global community to create something that’s flexible for all building types and organizational priorities. This consistency across market sectors means people will see the seal at their favorite restaurants, stadiums and hotels, and at their office, childcare center or college campus and know it stands for the same thing in every location, that science-based strategies have been implemented and safety has been prioritized.”

The WELL Health-Safety Rating was developed in response to market demand and informed by IWBI’s Task Force on COVID-19, which included nearly 600 public health experts, virologists, government officials, academics, business leaders, architects, designers, building scientists and real estate professionals. More than 1.5 billion square feet of space are enrolled in WELL offerings. To date, Yankee Stadium, the Empire State Building, JPMorgan Chase, RocketMortgage Field House, Amalie Arena, Spectrum Center, Simon Property Group, BB&T Center, Aimbridge Hospitality and AT&T Stadium, among others, have achieved the WELL Health-Safety Rating.

The public awareness campaign launched today and comes to life through TV, digital video and social advertising. TV commercials will appear nationally through early spring 2021. The campaign creative was developed by advertising agency SWAT by Kirshenbaum, directed by Spike Lee and produced by Pony Show Entertainment.

“From an enterprise standpoint, this is an exceptionally exciting time for all of us,” said Delos CMO Anthony Antolino. “Helping everyone to get back to business with confidence is critical, and these celebrity ambassadors are key in helping spread the word.”

For more information about the campaign, please visit www.WellHealthSafety.com.

About the International WELL Building Institute
The International WELL Building Institute (IWBI) is a public benefit corporation and the world’s leading organization focused on deploying people first places to advance a global culture of health. The WELL Building Standard anchors a WELL ecosystem that includes WELL v2, the WELL Community Standard, the WELL Health-Safety Rating and WELL Accredited Professionals. IWBI mobilizes its community through the pursuit of applicable research, the development of educational resources, and advocacy for policies that promote health and well-being for everyone, everywhere. More information on WELL can be found here.

International WELL Building Institute, IWBI, the WELL Building Standard, WELL v2, WELL Certified, WELL AP, WELL Portfolio, The WELL Conference, the WELL Community Standard, WELL Workforce, WELL Health-Safety Rating, WE ARE WELL, WELL and others, and their related logos are trademarks or certification marks of International WELL Building Institute pbc in the United States and other countries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Samantha Wolf
Tel. 646-935-4032
samantha.wolf@ketchum.com

Jamie Matos
media@wellcertified.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye